Stay updated with breaking news from Pardes Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) – Investment analysts at SVB Leerink decreased their Q1 2023 earnings per share estimates for Pardes Biosciences in a report issued on Monday, April 3rd. SVB Leerink analyst R. Ruiz now forecasts that the company will earn ($0.38) per share for the quarter, down from their previous estimate […]
Despite Months of Private Engagement From Irenic and Presumably Other Investors, Chairman CEO Rick E. Winningham and Theravance's Board Refuse to Act in Shareholders' Best Interests Notes Theravance's
Ascletis Pharma (ASCLF) said China's National Medical Products Administration ((NMPA)) approved its investigational new drug ((IND)) application for starting a trial of oral drug ASC11...
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1... | September 13, 2022
CARLSBAD, Calif., Sept. 12, 2022 -- Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug... | September 12, 2022